Format

Send to

Choose Destination
Drug Discov Today. 2016 May;21(5):843-9. doi: 10.1016/j.drudis.2016.03.007. Epub 2016 Mar 16.

Curcumin as a therapeutic agent in the chemoprevention of inflammatory bowel disease.

Author information

1
Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata City 956-8603, Japan. Electronic address: sreedharremya@gmail.com.
2
Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata City 956-8603, Japan.
3
Department of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, TX 77030, USA.
4
Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata City 956-8603, Japan. Electronic address: watanabe@nupals.ac.jp.

Abstract

Inflammatory bowel diseases (IBD), mainly Crohn's disease (CD) and ulcerative colitis (UC) are chronic ailments of the gastrointestinal tract, characterized by recurrent inflammation. Current therapeutic strategies are based on the mitigation of symptoms, including inflammatory remission and healing of mucosal manifestations. Extensive studies have suggested that continuous oxidative damage can lead to the inflammatory signaling cascade in IBD. Curcumin, a potent modulator of cell signaling, is popular for its antioxidant and anti-inflammatory activities, and has already been shown remarkable therapeutic results in IBD. Here, we review and discuss the effects of curcumin as a therapeutic agent in the chemoprevention of IBD.

PMID:
26995272
DOI:
10.1016/j.drudis.2016.03.007
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center